STING1 and neoplasm: This dysregulation likely contributes to immune evasion, allowing cancer cell proliferation without triggering antiviral and anti-tumor responses, highlighting the potential of STING/IRF3 modulation for restoring immune surveillance in ovarian cancer (Figure 4) (62).